PAR4 antagonist 8

PAR4 antagonist 8 (Compound 20f) is an effective, orally active, and selective PAR4 antagonist with an IC50 value of 15.32 nM. PAR4 antagonist 8 exhibits favorable pharmacokinetic properties. PAR4 antagonist 8 not only effectively inhibits human platelet aggregation induced by PAR4 agonists (IC50 = 6.39 nM) but also inhibits mouse platelet aggregation. PAR4 antagonist 8 can be used in antithrombotic research[1].

Product Specifications

UNSPSC

12352005

Target

Protease Activated Receptor (PAR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/par4-antagonist-8.html

Smiles

COC1=NC2=CC(C)=CC(C3=NC4=C(S3)C(C[C@@H](O5)COC(NC6=CC(F)=CC(C#N)=C6)=O)=C5C(F)=C4)=C2C=N1

Molecular Formula

C28H19F2N5O4S

Molecular Weight

559.54

References & Citations

[1]Li S, et al. Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability[J]. European Journal of Medicinal Chemistry, 2024, 280: 116980.